This page will appear automatically.
An investigational triple-receptor agonist for metabolic research.
R3T is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. It is being studied in controlled clinical programmes for weight, appetite and wider metabolic outcomes.
Its triple-agonist design combines incretin signalling with glucagon-receptor activity. Researchers are examining how this may affect appetite, energy balance, glucose regulation and body weight.
studies in people are still developing, but findings relate to the studied medicine, manufacturing controls, eligibility criteria and monitored regimens. They do not establish equivalence with a separate presentation.
R3T remains investigational and has no standard cycling model. Trial averages cannot predict individual response, and dose escalation can materially affect tolerability.
Gastrointestinal effects, dehydration, gallbladder or pancreatic concerns, glucose changes and heart-rate increases require appropriate medical oversight. Pen strength is not a dose recommendation.
Published or handbook ranges do not establish individual suitability or directions.
Health conditions, medicines, allergies and monitoring needs require individual consideration.
Storage: Store refrigerated at 2 to 8°C, protected from light. Do not freeze. Follow the batch-specific label and handling information supplied with the product.
No. Reference amounts describe source-reported research context only, not a personal recommendation.
Grade D describes how much information is available, not whether R3T is right for you. See the evidence section above for detail.
Ordering is not currently available through this site. Enquire and our team will advise on availability in your market.
Contact our support team with the product name and batch reference and we'll help directly.
